SRTS
What one share of Sensus Healthcare holds
Surgical and Medical Instruments and Apparatus
“we,” “us,” “our,” or the “Company”) is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on decades of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM,
Sensus Healthcare’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.07 |
|---|---|
| Profit | −$0.94 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.43 |
| Cash and investments | $0.92 |
| Book value | $2.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.23 | −$0.03 | $0.02 | −$0.09 | — | $1.13 |
| 2017 | $1.56 | −$0.28 | $0.02 | −$0.25 | — | $0.87 |
| 2018 | $1.87 | −$0.14 | $0.06 | −$0.67 | — | $1.64 |
| 2019 | $1.68 | −$0.10 | $0.02 | −$0.15 | — | $1.70 |
| 2020 | $0.58 | −$0.42 | $0.02 | −$0.05 | — | $1.30 |
| 2021 | $1.64 | $0.25 | $0.01 | −$0.03 | — | $1.57 |
| 2022 | $2.68 | $1.46 | $0.01 | −$0.09 | — | $2.93 |
| 2023 | $1.50 | $0.03 | $0.01 | −$0.15 | — | $2.98 |
| 2024 | $2.56 | $0.41 | $0.02 | −$0.07 | — | $3.38 |
| 2025 | $1.68 | −$0.47 | $0.01 | $0.02 | — | $2.92 |